BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Rinat (Pfizer Global Research and Development) 

230 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-615-7300 Fax: 650-615-7350


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Rinat, located in South San Francisco, CA, is now a part of Pfizer’s Biotherapeutics and Bioinnovation Center (BBC). The center is both independent and interdependent on Pfizer Global Research and Development (PGRD), creating and overseeing a federation of units and collaborations with the academic, biomedical, biotech communities, while collaborating closely with PGRD to discover and develop protein therapeutics that address significant unmet medical needs.
At Rinat, we are dedicated to looking at diseases in novel ways to discover new medicines in the quest to design better treatment options for patients suffering from life-threatening and life-altering diseases.

Research at Rinat incorporates the disciplines of protein engineering and biology, and our scientists work closely to bring novel protein-based therapeutics from the bench through to the clinic. By studying the functions and interactions of proteins implicated in human diseases, our protein engineers design drug candidates that are best equipped to fight those diseases, while our biologists use innovative techniques to evaluate the safety and efficacy of the candidates in both in vitro and in vivo studies.

The integration of protein therapeutics into the drug discovery process enables Rinat scientists to potentially both design more successful medicines and significantly reduce the amount of time it takes to bring those new medicines to patients – a process that can take upwards of 10 years.

Rinat was formed in 2001 when Genentech narrowed its focus and spun out its key neuroscience assets under a broad license to Rinat. In 2006, Pfizer expanded biotherapeutic research and acquired Rinat.

The Rinat research group offers an exciting challenge for those who are committed to finding new and improved ways to treat diseases – the impact of which has the potential to be felt around the world.

Last Updated: 03-12-2008


 Key Statistics


Email: rinathr@pfizer.com
Ownership:

Web Site: Rinat (Pfizer Global Research and Development)
Employees: 80
Symbol: PFE
 



Industry
Biotechnology






 Company News
The Day In Review: Pfizer Inc. (PFE) Buys Another Biotech 4/7/2006 5:19:50 PM
Pfizer Inc. (PFE) To Acquire Rinat Neuroscience Corporation 4/7/2006 10:26:47 AM
Rinat Neuroscience Corporation Names Management Team Additions, Promotion10/19/2005 5:13:04 PM
Genentech, Inc. (DNA) And Rinat Neuroscience Corporation Announce Co-Development And Joint Commercialization Agreement For Anti-NGF Antibody For Acute And Chronic Pain10/19/2005 5:12:07 PM
Rinat Neuroscience Adds Chief Business Officer And Vice President, Clinical Development10/19/2005 5:10:52 PM
PHT Corporation LogPad Chosen By Rinat Neuroscience For First In-Human Trial; Reaching Over 100 Trial Implementations For PHT10/19/2005 5:08:59 PM
Rinat Neuroscience Corporation Begins Clinical Testing Of Potential First-In-Class Pain Therapeutic10/19/2005 5:08:49 PM